drugset / Trial / NCT02063139

Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

NCT02063139

Phase 2 Completed 48 enrolled Mundipharma Research Limited
RandomizedCrossoverSingle-blindTreatment

Summary

Aim of the study is to investigate the short-term growth in children with asthma aged 5-11 years in treatment with fluticasone propionate / formoterol spray (flutiform®) 200/20 micrograms per day

Timeline

Start
2014-02
Primary completion
2014-06
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclomethasone Small molecule 50 ug Inhaled
Comparator Fluticasone Other / unclassified 50 ug Inhaled
Subject Flutiform Unknown Inhaled

Indications